



PRESS RELEASE

SENO Rx ANNOUNCES FIRST PEER-REVIEWED PUBLICATIONS OF CLINICAL FINDINGS RELATED TO ITS CONTURA™ MLB

IRVINE, Calif., April 2, 2009 -- SenoRx (Nasdaq: SENO) today announced that two peer-reviewed journal articles summarizing clinical findings related to its Contura™ Multi-Lumen Balloon (MLB) Catheter are pending publication. These and other studies support our belief that a patient treated with Contura MLB receives a more targeted dose of radiation, while minimizing radiation to healthy tissue such as the skin and ribs. As a result, more patients are being treated with Contura MLB who previously were not candidates for accelerated partial breast radiation therapy. One article was published in *Brachytherapy* and a second has been accepted for publication in *The American Surgeon*:

“Initial Radiation Experience Evaluating Early Tolerance and Toxicities in Patients Undergoing Accelerated Partial Breast Irradiation Using the Contura™ Multi-Lumen Balloon (MLB) Breast Brachytherapy Catheter” – Authors: Brown, S.; McLaughlin, M.; Pope, K.; Haile, K.; Whitaker T.; Hughes, L.; and Israel, P. – presented at San Antonio Breast Cancer Symposium (SABCS), December 2008, and in press in *Brachytherapy*, February 2009.

“Initial Surgical Experience Evaluating Early Tolerance and Toxicities in Patients Undergoing Accelerated Partial Breast Irradiation Using the Contura™ Multi-Lumen Balloon (MLB) Breast Brachytherapy Catheter” – Authors: Israel, P.; Robbins, A.; Shroff, P.; Haile, K.; and Pope, K. – presented at Society of Surgical Oncology (SSO), March 2009, and accepted for publication in *The American Surgeon*.

Since the beginning of 2009, six additional abstracts have been or are scheduled for presentation at major industry meetings:

“Clinical Improvements in Accelerated Partial Breast Irradiation using the Contura™ Balloon Applicator” – Authors: Trombetta, M.; Julian, T.B.; Golesorkhi, N.; Werts, E.D.; Kim, Y.; Betler, J.; and Parada, D. – presented at American College of Radiation Oncology (ACRO), February 2009.

“A Contura Multi-Lumen Catheter Offers Important Dosimetric Advantages Over a MammoSite Single-Lumen Catheter that Increase the Applicability of Accelerated Partial Breast Irradiation” – Authors: Curcio, L.; Khanijou, R.; Eisner,

M.; Kakkis, J.; Chittenden, L.; Mesa, A.; Ravera, J.; Tokita, K.; and Wilder, R. – presented at Miami Breast Cancer Conference (MBCC), March 2009.

“Preliminary Single Institutional Clinical Experiences with the Contura™ Multi-Lumen Brachytherapy (MLB) Applicator” - Authors: Golesorkhi, N.; Kim, Y.; Trombetta, M.G.; Werts, E.D.; and Julian, T.B. – presented at Society of Surgical Oncology (SSO), March 2009.

“Use of a Contura Catheter for Accelerated Partial Breast Irradiation in “Intermediate-Risk” Breast Cancer Patients” – Authors: Mesa, A.V.; Tokita, K.M.; Chittenden, L.; Agustin, J.K.; Curcio, L.D.; Khanijou, R.K.; Kakkis, J.L.; Eisner, M.E.; Ravera, J.; and Wilder, R.B. – to be presented at American Radium Society (ARS), April 2009.

“Initial Dosimetric Experience: Contura Multi-Lumen Balloon (MLB) Registry Trial” – Authors: Arthur, D.W.; Vicini, F.A.; Todor, D.; and Julian, T.B. – to be presented at American Brachytherapy Society (ABS), June 2009.

“A Comparison of Skin and Chest Wall Dose Delivered with Multi-Catheter (MC), Contura Multi-Lumen Balloon (MLB), and MammoSite (MS) Breast Brachytherapy” – Authors: Cuttino, L.W.; Todor, D.T.; Heffernan, J.; Vera, R.; and Arthur, D.W. – to be presented at American Brachytherapy Society (ABS), June 2009.

“These papers and abstracts along with others already published or presented will be helpful in supporting our ongoing promotion of Contura MLB,” said Lloyd Malchow, SenoRx President and Chief Executive Officer. “We are also pleased that over 30 sites are participating in our Contura MLB Registry Study in which 136 patients are currently enrolled.”

About SenoRx

SenoRx (NASDAQ: SENO) develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis and treatment of breast cancer, including its EnCor® vacuum-assisted breast biopsy system and Contura™ MLB catheter for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer. SenoRx’s field sales organization serves over 1,000 breast diagnostic and treatment centers in the United States and Canada. In addition, SenoRx sells several of its products through distribution partners in more than 30 countries outside the U.S. and Canada. The company’s line of breast care products includes biopsy disposables, biopsy capital equipment, diagnostic adjunct products and therapeutic disposables. SenoRx is developing additional minimally invasive products for the diagnosis and treatment of breast cancer. For more information, visit the company’s website at www.senorx.com.

CONTACT: SenoRx, Inc.
Lila Churney, Director of Investor Relations
949-362-4800 x132